A novel approach to anticancer therapies: Peroxisome proliferator activator-receptor-γ as a new target therapy in the treatment of human urological cancer

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 76-83

  Matsuyama, M ^a   Yoshimura, R ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bladder tumor; Peroxisome proliferator activator receptor ; Prostate cancer; Renal cell carcinoma; Testicular cancer

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER TUMOR; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NONHUMAN; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TESTIS CANCER; URINARY TRACT CANCER; DRUG EFFECT; KIDNEY TUMOR; MALE; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; TESTIS TUMOR;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MALE; PPAR GAMMA; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 65549104658     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009787582432     Document Type: Article

References (25)

1. Sano, H.; Kawahito, Y.; Wilder, R.L.; Hashimoto, A.; Mukai, S.; Asai, K.; Kimura, S.; Kato, H.; Kondo, M. and Hla, T. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55(17), 3785-3789.
2. Inoue, K.; Kawahito, Y.; Tsubouchi, Y.; Kohno, M.; Yoshimura, R.; Yoshikawa, T. and Sano, H. (2001) Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun., 287(3), 727-732.
3. Yoshimura, R.; Matsuyama, M.; Segawa, Y.; Hase, T.; Mitsuhashi, M.; Tsuchida, K.; Wada, S.; Kawahito, Y.; Sano, H. and Nakatani, T. (2003) Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int. J. Cancer, 104(5), 597-602.
4. Segawa, Y.; Yoshimura, R.; Hase, T.; Nakatani, T.; Wada, S.; Kawahito, Y.; Kishimoto, T. and Sano, H. (2002) Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate, 51(2), 108-116.
5. Hase, T.; Yoshimura, R.; Mitsuhashi, M.; Segawa, Y.; Kawahito, Y.; Wada, S.; Nakatani, T. and Sano, H. (2002) Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology, 60(3), 542-547.
6. Yoshimura, R.; Matsuyama, M.; Hase, T.; Tsuchida, K.; Kuratsukuri, K.; Kawahito, Y.; Sano, H., Segawa, Y. and Nakatani, T. (2003) The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int. J. Mol. Med., 12(6), 861-865.
7. Kawahito, Y.; Kondo, M.; Tsubouchi, Y.; Hashiramoto, A.; Bishop-Bailey, D.; Inoue, K.; Kohno, M.; Yamada, R.; Hla, T. and Sano, H. (2000) 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest., 106(2), 189-197.
8. Bosari, S.; Lee, A.K.; DeLellis, R.A.; Wiley, B.D.; Heatley, G.J. and Silverman, M.L. (1992) Microvessel quantitation and prognosis in invasive breast carcinoma. Hum. Pathol., 23(7), 755-761.
9. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G. and Wahli, W. (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 68(5), 879-87.
10. Kliewer, S.A.; Umesono, K.; Noonan, D.J.; Heyman, R.A. and Evans, E.M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 358(6389), 771-774.
11. Kliewer, S.A.; Forman, B.M.; Blumberg, B.; Ong, E.S.; Borgmeyer, U.; Mangelsdorf, D.J.; Umesono, K. and Evan, R.M. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA, 91(15), 7355-7359.
12. Chinetti, G.; Griglio, S.; Antonucci, M.; Torra, I.P.; Delerive, P.; Majd, Z.; Fruchart, J.C.; Chapman, J.; Najib, J. and Staels, B. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem., 273(40), 25573-25580.
13. 2. J Biol Chem,, 274(24), 17042-17048.
14. Keelan, J.A.; Sato, T.A.; Marvin, K.W.; Lander, J.; Gilmour, R.S. and Mitchell, M.D. (1999) 15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem. Biophys. Res. Commun., 262(3), 579-585.
15. Altiok, S.; Xu, M. and Spiegelman, B.M. (1997) PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev., 11(15), 1987-1998.
16. Xin, X.; Yang, S.; Kowalski, J. and Gerritsen, M.E. (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem., 274(13), 9116-9121.
17. Boehm, T.; Folkman, J.; Browder, T. and O'Reilly, M.S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390(6658), 404-407.
18. O'Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.E.; Flynn, E.; Birkhead, J.R.; Olsen, B.R. and Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88(2), 277-285.
19. Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Muller, M.; Wood, J.; Martiny-Baron, G.; Unger, C. and Marme, D. (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res., 60(17), 4819-4824.
20. Yang, F.G.; Zhang, Z.W.; Xin, D.Q.; Shi, C.J.; Wu, X.Q.; Liu, W.J.; Guo, Y.L. and Wu, J.P. (2004) Peroxisome proliferator-actived receptor-gamma ligand troglitazone induces apoptosis in renal cell carcinoma. Beijing Da Xue Xue Bao, 36(2), 173-176.
21. Possati, L.; Rocchetti, R.; Talevi, S.; Beatrici, V.; Margiotta, C.; Ferrante, L.; Calza, R.; Sagrini, D. and Ferri, A. (2000) The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression. Gen. Pharmacol., 35(5), 269-275.
22. Oh, W.K. and Kantoff, P.W. (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160(4), 1220-1229.
23. Paltoo, D.; Woodson, K.; Taylor, P.; Albanes, D.; Virtamo, J. and Tangrea, J. (2003) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett., 191(1), 67-74.
24. Subbarayan, V.; Sabichi, A.L.; Kim, J.; Llansa, N.; Logothetis, C.J.; Lippman, S.M. and Menter, D.G. (2004) Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol. Biomarkers Prev., 13(11), 1710-1716.
25. 2. Cell Growth Differ., 11(1), 49-61.